Catalyst Event
Genscript Biotech Corp (1548) · Other
From Akros SCHK HK-Korea Biotech Index (ASHKBIO)
5/12/2026, 12:00:00 AM
Announced that its associate, Legend Biotech (LEGN), reported strong Q1 2026 results on May 12, 2026, with CARVYKTI net sales increasing 62% year-over-year to approximately $597 million and a narrowed net loss.
Korean Translation
관계사 레전드 바이오텍(LEGN)이 2026년 5월 12일 강력한 2026년 1분기 실적을 발표했다고 공시함. CARVYKTI 순매출은 전년 동기 대비 62% 증가한 약 5억 9,700만 달러를 기록했으며 순손실 폭은 감소함.
Related Recent Events
3SBio Inc (1530) · Earnings Release
First half 2026 earnings results are expected to be released around August 26, 2026, expected. High importance is estimated due to the significant impact of previous earnings growth on stock volatility.
8/26/2026, 12:00:00 AM
3SBio Inc (1530) · Other
The ex-dividend date for the final cash dividend of HKD 0.25 per share for the fiscal year 2025 is July 21, 2026, scheduled.
7/21/2026, 12:00:00 AM
Sino Biopharmaceutical Ltd (1177) · Other
The ex-dividend date for the proposed final dividend of HKD 0.05 per share is 2026-06-24, which is estimated to have a price impact of ≥1% scheduled.
6/24/2026, 12:00:00 AM
Innovent Biologics Inc (1801) · Other
Innovent will present obesity pipeline data at the ADA Scientific Sessions on June 5-8, 2026; this low-impact event is scheduled
6/5/2026, 12:00:00 AM
Giant Biogene Holding Co Ltd (2367) · Other
Ex-dividend date of 2026-06-01 for final and special dividends, scheduled. (Estimated Low impact as dividend is standard).
6/1/2026, 12:00:00 AM
D&D Pharmatech Inc (347850) · Other
The 48-week top-line results from the Phase 2 clinical trial of 'DD01', a MASH treatment, are scheduled to be presented at the European Association for the Study of the Liver (EASL) Congress 2026 (May 27-30) as a Late-Breaking Abstract; high impact is estimated due to the significant market potential for MASH treatments, which is expected.
5/27/2026, 12:00:00 AM